Compugen Ltd.

NASDAQ:CGEN

Biotechnology

Healthcare
$1.96 +0.50%

+$0.01 today

Market cap
$185.66M
Beta
2.74
P/E (TTM)
5.4
EPS (TTM)
$0.37
52W Low $1.30High $3.24

Volume 0.15M

Average 0.48M

CGEN Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Compugen Ltd.NASDAQ: CGEN

Capital Expenditures · Q4 FY2025 · quarter ended Dec 2025

Capital expenditures of $0 in Q4 FY2025

Q4 FY2025 capital expenditures was $0. Trailing-twelve-month capital expenditures was $0. Over 3 fiscal years it compounded at -14.3% a year.

Context

  • Capital expenditures amounted to 0.4% of revenue in FY2025, unchanged from a year earlier.
  • Capital expenditures grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly capital expenditures holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
$0— QoQ
Last fiscal yearDec 2025
-$306K+159.3% YoY
LTMDec 2025
$0— YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+159.3%——
3-year CAGR-14.3%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(306K) USD
Year-over-year change
-159.3%

Capital Expenditures vs competitors

How CGEN compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Capital expenditures amounts to 0.0% of revenue for CGEN, versus a peer median of 4.8%.
CGEN Competitors
Capital Expenditures for CGEN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TNXPTonix Pharmaceuticals Holding Corp.LTM Mar 2026$7.07M USD+43424.1%-58.8%40.3%
MOLNMolecular Partners AGLTM Mar 2026CHF 333.55K CHF-67.9%-20.4%—
IPHAInnate Pharma S.A.FY2025€134.47K EUR-65.6%-50.7%4.8%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$68.98K USD+76.9%+3.5%3.9%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$52K USD-82.7%-62.1%1.6%
CRDFCardiff Oncology, Inc.LTM Mar 2026$44K USD—-63.3%8.4%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$13K USD—-19.6%—
CGENCompugen Ltd.LTM Dec 2025$0 USD—-14.3%0.0%
NVCTNuvectis Pharma, Inc.LTM Mar 2026$0 USD———
Peer median (excluding CGEN) —-65.6%-50.7%4.8%

Competitors are the stored peer set for CGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(34.2M)(33.69M)(18.75M)(14.23M)35.34M
Depreciation & Amortization461K482K476K486K475K
Deferred Income Tax00000
Stock-Based Compensation4.28M4.33M3.55M3.02M0
Change in Working Capital6.82M(5.55M)(20.71M)62.05M(5.35M)
Accounts Receivables2M3.04M(61.11M)59.93M360K
Inventory(3.37M)0000
Accounts Payables3.37M(1.6M)3.51M(4.41M)517K
Other Working Capital3.79M(7M)36.9M6.53M(6.23M)
Other Non-Cash Items(573K)515K(452K)(1.72M)1.16M
Operating Cash Flow(22.75M)(34.51M)(35.89M)49.6M31.63M
Capital Expenditures(292K)(487K)(172K)(118K)(306K)
Acquisitions (Net)3K2K001K
Purchases of Investments(129.95M)(76.9M)(53.71M)(159.75M)(96.07M)
Sales of Investments136.85M114.45M89.39M113.95M126.37M
Other Investing Activities000(329K)0
Investing Cash Flow6.62M37.06M35.51M(46.25M)30M
Debt Repayment00000
Common Stock Issued14.96M353K3.08M544K10.61M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.88M0010K(4K)
Financing Cash Flow16.84M353K3.08M554K10.6M
Effect of Forex Changes469K(584K)129K68K135K
Net Change in Cash704K2.91M2.83M3.97M72.37M
Free Cash Flow(23.04M)(34.99M)(36.06M)49.49M31.33M

Compugen Ltd.

NASDAQ:CGEN

Intrinsic Alpha fair value

Locked

Current Price

$1.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.